Pliant Therapeutics, Inc. $PLRX Shares Acquired by Monaco Asset Management SAM

Monaco Asset Management SAM increased its holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) by 135.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,938,747 shares of the company’s stock after acquiring an additional 1,116,054 shares during the quarter. Monaco Asset Management SAM owned approximately 3.15% of Pliant Therapeutics worth $2,365,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the business. Rangeley Capital LLC lifted its stake in shares of Pliant Therapeutics by 20.4% in the second quarter. Rangeley Capital LLC now owns 60,220 shares of the company’s stock worth $70,000 after acquiring an additional 10,220 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in Pliant Therapeutics by 15.7% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 113,383 shares of the company’s stock valued at $138,000 after buying an additional 15,349 shares during the last quarter. Algert Global LLC increased its holdings in Pliant Therapeutics by 17.7% in the third quarter. Algert Global LLC now owns 104,382 shares of the company’s stock valued at $154,000 after buying an additional 15,692 shares during the last quarter. Engineers Gate Manager LP increased its holdings in Pliant Therapeutics by 139.4% in the second quarter. Engineers Gate Manager LP now owns 31,423 shares of the company’s stock valued at $36,000 after buying an additional 18,300 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in Pliant Therapeutics by 42.2% in the first quarter. Invesco Ltd. now owns 68,963 shares of the company’s stock valued at $93,000 after buying an additional 20,449 shares during the last quarter. Institutional investors and hedge funds own 97.30% of the company’s stock.

Analyst Ratings Changes

PLRX has been the subject of several research analyst reports. Wall Street Zen raised Pliant Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Pliant Therapeutics in a report on Tuesday, April 21st. Piper Sandler lowered their price objective on Pliant Therapeutics from $4.00 to $3.00 and set an “overweight” rating for the company in a report on Thursday, March 12th. Finally, Canaccord Genuity Group lowered their price objective on Pliant Therapeutics from $4.00 to $3.00 and set a “hold” rating for the company in a report on Friday, March 13th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Pliant Therapeutics presently has an average rating of “Reduce” and an average price target of $3.00.

Pliant Therapeutics Price Performance

Shares of Pliant Therapeutics stock opened at $1.26 on Monday. The firm has a market cap of $78.02 million, a P/E ratio of -0.68 and a beta of 1.20. The business has a 50-day moving average price of $1.25 and a 200 day moving average price of $1.30. Pliant Therapeutics, Inc. has a fifty-two week low of $1.09 and a fifty-two week high of $1.95.

Pliant Therapeutics (NASDAQ:PLRX) last posted its earnings results on Monday, May 11th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.04. As a group, equities research analysts anticipate that Pliant Therapeutics, Inc. will post -1.37 earnings per share for the current year.

Pliant Therapeutics Profile

Pliant Therapeutics, Inc (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems.

The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both ?v?1 and ?v?6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).